Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4a95c7328e9c63a07ce2de92c34d8f0 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 |
filingDate |
2001-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5a83e4306bb79f982d7804a27591226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f511776c97c6c2b80d38f18b09373f86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b799935e3bb1c124b4b60c4c14c18d |
publicationDate |
2001-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2398840-A1 |
titleOfInvention |
Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
abstract |
The use of estramustine phosphate and its metabolites estramustine and estromustine allow to potentiate the therapeutic efficacy of taxanes by both improving their pharmacokinetic and pharmacodynamic profile through the inhibition of (CYP)2C8 and (CYP)3A4 enzymes, both responsible for the metabolism of the taxanes; formulations of estramustine phosphate and metabolites, combinations of these latter with taxanes and therapeutic methods of treatment comprising them as a combined therapy are also disclosed. |
priorityDate |
2000-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |